US 11,673,970 B2
Bi-specific fusion proteins
Ulrik Bjerl Nielsen, Quincy, MA (US); Thomas Wickham, Groton, MA (US); Birgit Schoeberl, Cambridge, MA (US); Brian Harms, Roslindale, MA (US); Bryan Linggi, Richland, WA (US); Matthew Onsum, Jamaica Plain, MA (US); and Byron DeLaBarre, Cambridge, MA (US)
Assigned to Silver Creek Pharmaceuticals, Inc., San Francisco, CA (US)
Filed by Silver Creek Pharmaceuticals, Inc., San Francisco, CA (US)
Filed on Oct. 23, 2020, as Appl. No. 17/78,978.
Application 17/078,978 is a division of application No. 15/957,252, filed on Apr. 19, 2018, granted, now 10,858,450.
Application 15/957,252 is a division of application No. 14/187,728, filed on Feb. 24, 2014, granted, now 9,982,060, issued on May 29, 2018.
Application 14/187,728 is a division of application No. 13/112,907, filed on May 20, 2011, granted, now 8,691,771, issued on Apr. 8, 2014.
Claims priority of provisional application 61/347,040, filed on May 21, 2010.
Prior Publication US 2021/0040233 A1, Feb. 11, 2021
Int. Cl. B82Y 5/00 (2011.01); C07K 14/475 (2006.01); A61K 47/66 (2017.01); A61K 47/68 (2017.01); C07K 16/46 (2006.01); C07K 14/47 (2006.01); C07K 14/65 (2006.01); A61K 38/00 (2006.01); C07K 16/44 (2006.01); C12N 15/62 (2006.01); A61K 45/06 (2006.01); C07K 14/485 (2006.01)
CPC C07K 16/46 (2013.01) [A61K 45/06 (2013.01); A61K 47/66 (2017.08); A61K 47/6811 (2017.08); A61K 47/6891 (2017.08); B82Y 5/00 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 14/485 (2013.01); C07K 14/65 (2013.01); C07K 16/44 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/80 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A bi-specific fusion protein comprising:
(a) an anti-phosphatidylserine scFv comprising an amino acid sequence having at least 90% identity with SEQ ID NO: 30; and
(b) an insulin-like growth factor 1 (IGF-1) comprising an amino acid sequence having at least 90% identity with SEQ ID NO: 5.